Fundies.
English

Segment disclosures

Company overview

SALARIUS PHARMACEUTICALS, INC.

Each reported dimension combination stays separate. Revenue and operating income are shown as reported, with their dates and sources.

Revenue · Reported segment facts

5 dimension combinations 68 retained observations 19 reported periods

Counts describe retained dimensioned rows only. Periods and members can change across reports, and this view does not infer missing values or expected segment totals.

Operating Segments · Consumer Operations

Consolidation Items · Statement Business Segments

Source dimensions srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:StatementBusinessSegmentsAxis=flks:ConsumerOperationsMember
PeriodValueUnitFiledEvidence
2019-04-01 – 2019-06-30164705 USD20190717Open filing evidence
2019-01-01 – 2019-06-30269682 USD20190717Open filing evidence
2019-01-01 – 2019-03-31104977 USD20190501Open filing evidence
2018-01-01 – 2018-12-31838142 USD20190306Open filing evidence
2018-07-01 – 2018-09-30250991 USD20190214Open filing evidence
2018-01-01 – 2018-09-30675075 USD20190214Open filing evidence
2018-04-01 – 2018-06-30245502 USD20190717Open filing evidence
2018-01-01 – 2018-06-30424084 USD20190717Open filing evidence
2018-01-01 – 2018-03-31178582 USD20190501Open filing evidence
2017-01-01 – 2017-12-311274499 USD20190306Open filing evidence
2017-07-01 – 2017-09-30413601 USD20190214Open filing evidence
2017-01-01 – 2017-09-30991671 USD20190214Open filing evidence
2017-04-01 – 2017-06-30335523 USD20180801Open filing evidence
2017-01-01 – 2017-06-30578070 USD20180801Open filing evidence
2016-01-01 – 2016-12-311010663 USD20190306Open filing evidence

Operating Segments · Drug Development

Consolidation Items · Statement Business Segments

Source dimensions srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:StatementBusinessSegmentsAxis=flks:DrugDevelopmentMember
PeriodValueUnitFiledEvidence
2019-04-01 – 2019-06-300 USD20190717Open filing evidence
2019-01-01 – 2019-06-300 USD20190717Open filing evidence
2019-01-01 – 2019-03-310 USD20190501Open filing evidence
2018-01-01 – 2018-12-310 USD20190306Open filing evidence
2018-07-01 – 2018-09-300 USD20181105Open filing evidence
2018-01-01 – 2018-09-300 USD20181105Open filing evidence
2018-04-01 – 2018-06-300 USD20190717Open filing evidence
2018-01-01 – 2018-06-300 USD20190717Open filing evidence
2018-01-01 – 2018-03-310 USD20190501Open filing evidence
2017-01-01 – 2017-12-310 USD20190306Open filing evidence
2017-07-01 – 2017-09-300 USD20181105Open filing evidence
2017-01-01 – 2017-09-300 USD20181105Open filing evidence
2017-04-01 – 2017-06-300 USD20180801Open filing evidence
2017-01-01 – 2017-06-300 USD20180801Open filing evidence
2016-01-01 – 2016-12-310 USD20190306Open filing evidence

Operating Segments · Consumer Operations

Consolidation Items · Statement Business Segments

Source dimensions us-gaap:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:StatementBusinessSegmentsAxis=flks:ConsumerOperationsMember
PeriodValueUnitFiledEvidence
2018-01-01 – 2018-03-31178582 USD20180502Open filing evidence
2017-01-01 – 2017-12-311274499 USD20180307Open filing evidence
2017-07-01 – 2017-09-30413601 USD20171106Open filing evidence
2017-01-01 – 2017-09-30991671 USD20171106Open filing evidence
2017-04-01 – 2017-06-30335523 USD20170802Open filing evidence
2017-01-01 – 2017-06-30578070 USD20170802Open filing evidence
2017-01-01 – 2017-03-31242547 USD20180502Open filing evidence
2016-01-01 – 2016-12-311010663 USD20180307Open filing evidence
2016-07-01 – 2016-09-30599074 USD20171106Open filing evidence
2016-01-01 – 2016-09-30711759 USD20171106Open filing evidence
2016-04-01 – 2016-06-30112685 USD20170802Open filing evidence
2016-01-01 – 2016-06-30112685 USD20170802Open filing evidence
2016-01-01 – 2016-03-310 USD20170503Open filing evidence
2015-01-01 – 2015-12-310 USD20180307Open filing evidence
2015-07-01 – 2015-09-300 USD20161102Open filing evidence
2015-01-01 – 2015-09-300 USD20161102Open filing evidence
2014-02-26 – 2014-12-310 USD20170308Open filing evidence

Operating Segments · Drug Development

Consolidation Items · Statement Business Segments

Source dimensions us-gaap:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:StatementBusinessSegmentsAxis=flks:DrugDevelopmentMember
PeriodValueUnitFiledEvidence
2018-01-01 – 2018-03-310 USD20180502Open filing evidence
2017-01-01 – 2017-12-310 USD20180307Open filing evidence
2017-07-01 – 2017-09-300 USD20171106Open filing evidence
2017-01-01 – 2017-09-300 USD20171106Open filing evidence
2017-04-01 – 2017-06-300 USD20170802Open filing evidence
2017-01-01 – 2017-06-300 USD20170802Open filing evidence
2017-01-01 – 2017-03-310 USD20180502Open filing evidence
2016-01-01 – 2016-12-310 USD20180307Open filing evidence
2016-07-01 – 2016-09-300 USD20171106Open filing evidence
2016-01-01 – 2016-09-300 USD20171106Open filing evidence
2016-04-01 – 2016-06-300 USD20170802Open filing evidence
2016-01-01 – 2016-06-300 USD20170802Open filing evidence
2016-01-01 – 2016-03-310 USD20170503Open filing evidence
2015-01-01 – 2015-12-310 USD20180307Open filing evidence
2015-07-01 – 2015-09-300 USD20161102Open filing evidence
2015-01-01 – 2015-09-300 USD20161102Open filing evidence
2014-02-26 – 2014-12-310 USD20170308Open filing evidence

Reportable Segment

Statement Business Segments

Source dimensions us-gaap:StatementBusinessSegmentsAxis=dcoy:ReportableSegmentMember
PeriodValueUnitFiledEvidence
2026-04-01 – 2026-06-30227629 USD20260812Open filing evidence
2026-01-01 – 2026-06-30227629 USD20260812Open filing evidence
2025-04-01 – 2025-06-300 USD20260812Open filing evidence
2025-01-01 – 2025-06-300 USD20260812Open filing evidence